Research Tracker›Biomarker Atlas›Lyme Disease›Interleukin-6 (IL-6)

Interleukin-6 (IL-6) in Lyme Disease

In Lyme Disease (Lyme borreliosis, Borrelia burgdorferi infection), published studies report higher levels of Interleukin-6 (IL-6), also described as Pro-inflammatory cytokine, than in healthy controls. Clinically, it has been associated with active Borrelia infection. The evidence summarised here comes from Soloski et al. 2014 and reflects averages across cohorts rather than any single patient's result.

↑ ElevatedInflammatoryLOINC 26881-3

Summary

Direction in Lyme Disease↑ Elevated — higher than in the comparison group
CategoryInflammatory
Also described asPro-inflammatory cytokine
Compared againstHC (healthy controls)
Associated symptomsActive Borrelia infection
Test typeBlood test (serum / plasma / whole blood)
LOINC code26881-3
SourceSoloski et al. 2014 — doi:10.1371/journal.pone.0093243
Condition atlasLyme Disease Biomarker Atlas

Other conditions where Interleukin-6 (IL-6) is reported

Atlas entryDirectionCompared against
Interleukin-6 in Atrial Fibrillation↕ inconsistentvs AF patients vs. implied healthy/reference
Interleukin-6 in Epilepsy↑ elevatedvs not explicitly named (comparison implied by disease state vs. normal/control)
Interleukin-6 (IL-6) in Gulf War Illness↑ elevatedvs HGV
Interleukin-6 (IL-6) in Long COVID↑ elevatedvs HC, R
IL-6 in Low Back Pain↑ elevatedvs chronic nonspecific LBP vs asymptomatic controls
IL-6 in Major Depressive Disorder↑ elevatedvs females with depression vs healthy female controls
Interleukin-6 (IL-6) in ME/CFS↕ inconsistentvs HC
Interleukin-6 in Migraine↑ elevatedvs headache-free controls
IL-6 in PACVS↑ elevatedvs HC
IL-6 in Rheumatoid Arthritis↑ elevatedvs RA vs healthy (established inflammatory pathway/drug target)

See the cross-condition hub: Interleukin-6 (IL-6) across conditions.

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term Interleukin-6 (IL-6) (12 registered trials use a matching outcome measure).

Clinical trials using Interleukin-6 (IL-6) as an outcome

NCT05524532Completed
Effects of Immulina TM Supplements With PASC Patients
Outcome measure: Plasma IL-6 (Interleukin 6, pg/mL)
NCT06142253Recruiting
Water-based Activity to Enhance Recovery in Long COVID-19
Outcome measure: Change in Blood labs
NCT07278206Recruiting
Brain Stimulation in Long COVID
Outcome measure: Interleukin-6 (IL-6)
NCT06597682Not Yet Recruiting
Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction
Outcome measure: Change in IL-6 Levels
NCT06073002Active Not Recruiting
Effects of a Home-Based Exercise Intervention in Subjects with Long COVID
Outcome measure: Change of interleukin-6 (IL-6 measured in pg/ml)
NCT06064838Completed
Effects of Cacao Flavonoids in Long COVID-19 Patients (FLALOC)
Outcome measure: Interleukin-6
NCT05356936Completed
Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers
Outcome measure: Change in interleukin 6 (IL-6) as measured by blood test
NCT04751669Completed
Efficacy of a Dietary Supplementation in Reducing Hospital Admissions for COVID-19. Randomized Clinical Trial
Outcome measure: Inflammatory parameters

4 more trials reference this marker.

Interventions studied alongside this marker

Hypothesis-generating links from trial outcome usage and literature co-occurrence. Not treatment recommendations.

Commercial test availability

Interleukin-6 (IL-6), Serum — commercial laboratory test.

Links are for reference only; availability, specimen requirements and coverage vary by location.

Related Inflammatory markers in Lyme Disease

Full list: Lyme Disease Biomarker Atlas.

Frequently asked questions

Is Interleukin-6 (IL-6) high or low in Lyme Disease?

Elevated. Studies summarised in the OSMF atlas report higher Interleukin-6 (IL-6) in Lyme Disease than in healthy controls. Source: Soloski et al. 2014.

What symptoms is Interleukin-6 (IL-6) associated with in Lyme Disease?

The cited literature associates this marker with Active Borrelia infection. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Interleukin-6 (IL-6)?

It is measured as a blood test (serum / plasma / whole blood). The standard laboratory code is LOINC 26881-3. Commercial laboratories such as Quest Diagnostics, LabCorp, Ulta Lab Tests list an orderable assay.

Is one abnormal Interleukin-6 (IL-6) result diagnostic of Lyme Disease?

No. No single biomarker is diagnostic of Lyme Disease. Interleukin-6 (IL-6) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is Interleukin-6 (IL-6) specific to Lyme Disease?

No. The same marker is also reported in Atrial Fibrillation, Epilepsy, Gulf War Illness, Long COVID, Low Back Pain, ME/CFS, Major Depressive Disorder, Migraine, PACVS, Rheumatoid Arthritis in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). Interleukin-6 (IL-6) in Lyme Disease: direction, evidence and what it means. OSMF Research Tracker. Retrieved November 21, 2026, from https://research.opensourcemed.info/biomarkers/lyme/interleukin-6-il-6.html

Last reviewed: 2026-06-29 · Page generated from lyme.json · Browse: Lyme Disease atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.